Researchers discover how an executioner mechanism is triggered to kill damaged cells

NewsGuard 100/100 Score

Researchers led by St. Jude Children's Research Hospital structural biologists have discovered how the cell switches on an executioner mechanism called necroptosis that induces damaged or infected cells to commit suicide to protect the body.

Abnormal function of necroptosis also plays a role in the pathology of a broad array of diseases. Cancer cells avoid destruction by inhibiting necroptosis; and abnormal activation of necroptosis is linked to the damage from multiple sclerosis, Parkinson's disease and tissue injury from blood flow loss. Thus, the researchers' basic findings opens the pathways for drugs to treat those disorders by controlling necroptosis.

Led by structural biologist Tudor Moldoveanu, Ph.D., an assistant member of St. Jude Department of Structural Biology, the team included scientists from St. Jude, and the Stanford University and Vanderbilt University Schools of Medicine. The research was published today in the scientific journal Cell Chemical Biology.

Their research revealed how a set of molecules called inositol phosphates acts as an activating code, like the combination to a safe, to unleash the cell-killing mechanism of a molecule called MLKL. The activation triggers an "executioner domain" of the MLKL molecule to break down the integrity of the cell membrane and kill the cell.

Source: https://www.stjude.org/research/news-publications/research-highlights/2019-research-highlights/biological-machinery-of-cells-executioner-yields-secrets-of-control.html

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel immune cell therapy may be a promising strategy for combating HBV infection